Big pharma pulls the plug on development of heart and stroke drugs

October 20, 2008 by  

1 Star2 Stars3 Stars4 Stars5 Stars (No Ratings Yet)

Many pharmaceutical companies have made billions of dollars with blockbuster drugs used for the treatment of cardiovascular diseases. Among these drugs are statins and other cholesterol-lowering drugs. However, it seems that the profitable days are over. The therapeutic area of cardiovascular medicine seems to be less lucrative nowadays, what with many of the bestselling drugs going off-patent. The market is getting flooded with cheaper generic versions of the said drugs.

Pfizer is one of the pharma giants that feels that cardiovascular drugs are no longer profitable. According to an internal Pfizer memo obtained somehow by Forbes, the company has decided to focus the development of new drugs (and therefore R& D spending) on therapeutic areas which are considered to be potentially lucrative. These high priority areas are cancer, diabetes, pain killers, and neurological disorders, such as Alzheimer’s disease but do not include cardiovascular medicine.

Pfizer is one of the companies who are suffering from drug patents running out. Its anti-cholesterol drug Lipitor (atorvastatin), said to be the world’s bestselling drug, will lose its patent in about two years’ time (2011). The company has also lost the patent of another bestseller, Norvasc (amlodipine) in 2007. Other companies have similar problems. The blockbuster drugs whose patents are about to expire are Risperdal (Johnson & Johnson’s), Seroquel (Astra Zeneca), Lamictal (GSK), and Avandia (GSK).

The last two years witnessed a lot of safety issues in the pharmaceutical industry. It has not recovered yet from the Vioxx (rofecoxib) debacle and had to face the safety problems of Avandia (rosiglitazone) and the drug-eluting stents (DES), the disappointment over ENHANCE and ezetimibe, and the failure of the HIV vaccine.

In the field of cardiovascular medicine, the use of surrogate markers such as LDL- and HDL- cholesterol levels is being question.

So far, biomarker and stem cell research haven’t delivered any “miracle” diagnostics and treatments that everyone was hoping for. It will probably take years, even decades before biotechnology can produce something that will “rock” the medical world although several early phase clinical trials are planned or ongoing. In the current financial crisis, it is no wonder that pharma companies are becoming more cautious where they put their money.

Where does that leave cardiovascular patients? I think there is a wide range of drugs out there indicated for cardiovascular health. The main focus of the health care industry should not be pharmacological therapy but prevention and treatment through lifestyle change strategies. Practical ways where we can improve cardiovascular health without the aid of drugs and pharmaceutical companies are:

Photo credit: Stock.xchng by tanyah

Related Posts with Thumbnails
Print Friendly, PDF & Email
  • Winsor Pilates


2 Responses to “Big pharma pulls the plug on development of heart and stroke drugs”
  1. Dhoni says:

    Prevention is always the best thing. It’s cheaper,safer,practical, and has higher percentage of success rather than medication. Though the drugs price is getting lower, the price of prevention is still the lowest.

Speak Your Mind

Tell us what you're thinking...
and oh, if you want a pic to show with your comment, go get a gravatar!


Random Battling For Health Products From Our Store

NOTE: The contents in this blog are for informational purposes only, and should not be construed as medical advice, diagnosis, treatment or a substitute for professional care. Always seek the advice of your physician or other qualified health professional before making changes to any existing treatment or program. Some of the information presented in this blog may already be out of date.

Read previous post:
Think Before You Pink

With the growing popularity of pink products for the month of October, National Breast Cancer Awareness Month; have you ever...